Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Scancell Holdings ( (GB:SCLP) ).
Scancell Holdings plc announced that translational data from its ongoing Phase 2 SCOPE trial of SCIB1, a DNA plasmid melanoma cancer vaccine, will be presented at the AACR IO conference. The data showcases the efficacy of SCIB1 when combined with nivolumab and ipilimumab, demonstrating an 84% disease control rate and 80% progression-free survival in late-stage melanoma patients. This presentation is expected to validate SCIB1’s potential in cancer immunotherapy, potentially strengthening Scancell’s position in the industry and offering new hope for stakeholders, including patients and investors.
More about Scancell Holdings
Scancell Holdings plc is a clinical stage biopharmaceutical company focused on developing innovative cancer treatments by leveraging its proprietary research on the human adaptive immune system. The company aims to address unmet medical needs in cancer through its pipeline of novel medicines, utilizing its four technology platforms: Moditope® and ImmunoBody® for vaccines, and GlyMab® and AvidiMab® for antibodies.
YTD Price Performance: -14.42%
Average Trading Volume: 1,201,242
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £95.38M
For detailed information about SCLP stock, go to TipRanks’ Stock Analysis page.